Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 14Lymphoma 12Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 7Neoplasms 4Lymphoma, B-Cell 4Burkitt Lymphoma 4Recurrence 3Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasm, Residual 1Melanoma 1Mature B-cell Malignancies 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leukemia 1Heart Failure 1Extensive Stage Small Cell Lung Cancer 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

glofitamab 2Rituximab 2Cyclophosphamide 2zanubrutinib 1pirtobrutinib 1pegfilgrastim 1obinutuzumab 1mirabegron 1Vincristine 1Specimen Handling 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Lenalidomide 1Doxorubicin 1Dexrazoxane 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dendritic Cell Sarcoma, Interdigitating × obinutuzumab × Clear all
NCT04889716 2026-05-26

CAR-T Followed by Bispecific Antibodies

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
23 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡